Lazard Capital sees huge potential in GW Pharmaceuticals' epilepsy program

|About: GW Pharmaceuticals plc (GWPH)|By:, SA News Editor

Lazard Capital is excited about Sativex maker GW Pharmaceuticals (GWPH).

Market chatter suggests Joshua Schimmer has raised his price target on the shares to $65 (from $22) for upside potential of 163%.

Apparently, the company's Otsuka-partnered (OTSKF.OB) epilepsy program is "one of the most compelling opportunities [Lazard] has ever seen."

Here's what the company has to say about that program: "By studying the impact of cannabinoid addition on the amplitude of the epileptiforms produced, researchers are able to recognize if compounds could perform as an anti-epileptic drug in vivo."